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ABSTRACT
Objective: To explore pressure area related pain as a
predictor of category ≥2 pressure ulcer (PU)
development.
Design: Multicentre prospective cohort study.
Setting: UK hospital and community settings.
Participants inclusion: Consenting acutely ill
patients aged ≥18 years, defined as high risk (Braden
bedfast/chairfast AND completely immobile/very limited
mobility; pressure area related pain or; category 1 PU).
Exclusion: Patients too unwell, unable to report pain,
2 or more category ≥2 PUs.
Follow-up: Twice weekly for 30 days.
Primary and secondary outcome measures:
Development and time to development of one or more
category ≥2 PUs.
Results: Of 3819 screened, 1266 were eligible, 634
patients were recruited, 32 lost to follow-up, providing
a 602 analysis population. 152 (25.2%) developed one
or more category ≥2 PUs. 464 (77.1%) patients
reported pressure area related pain on a healthy, altered
or category 1 skin site of whom 130 (28.0%) developed
a category ≥2 PU compared with 22 (15.9%) of those
without pain. Full stepwise variable selection was used
throughout the analyses. (1) Multivariable logistic
regression model to assess 9 a priori factors: presence
of category 1 PU (OR=3.25, 95% CI (2.17 to 4.86),
p<0.0001), alterations to intact skin (OR=1.98, 95% CI
(1.30 to 3.00), p=0.0014), pressure area related pain
(OR=1.56, 95% CI (0.93 to 2.63), p=0.0931). (2)
Multivariable logistic regression model to account for
overdispersion: presence of category 1 PU (OR=3.20,
95% CI (2.11 to 4.85), p<0.0001), alterations to intact
skin (OR=1.90, 95% CI (1.24 to 2.91), p=0.0032),
pressure area related pain (OR=1.85, 95% CI (1.07 to
3.20), p=0.0271), pre-existing category 2 PU (OR=2.09,
95% CI (1.35 to 3.23), p=0.0009), presence of chronic
wound (OR=1.66, 95% CI (1.06 to 2.62), p=0.0277),
Braden activity (p=0.0476). (3) Accelerated failure time
model: presence of category 1 PU (AF=2.32, 95% CI
(1.73 to 3.12), p<0.0001), pressure area related pain
(AF=2.28, 95% CI (1.59 to 3.27), p<0.0001). (4) 2-level
random-intercept logistic regression model: skin status
which comprised 2 levels (versus healthy skin);
alterations to intact skin (OR=4.65, 95% CI (3.01 to
7.18), p<0.0001), presence of category 1 PU
(OR=17.30, 95% CI (11.09 to 27.00), p<0.0001) and
pressure area related pain (OR=2.25, 95% CI (1.53 to
3.29), p<0.0001).
Conclusions: This is the first study to assess pain as a
predictor of category ≥2 PU development. In all 4
models, pain emerged as a risk factor associated with an
increased probability of category ≥2 PU development.
INTRODUCTION
Background
A systematic review of health-related quality
of life in patients with pressure ulcers (PUs)
identiﬁed that patients reported experien-
cing pain at ‘pressure areas’ prior to clinical
PU manifestation but that their reports of
pain were ignored. Patients blamed health-
care professionals when a PU developed sub-
sequently, due to the lack of action.1 A PU
risk factor systematic review did not identify
any studies which included pain as a candi-
date risk factor in multivariable analysis,2 and
Strengths and limitations of this study
▪ The study was designed to incorporate key
quality criteria for the conduct and reporting of
risk factor/prognostic factor studies to promote
generalisability and minimise bias.
▪ The primary outcome, the development of new
category ≥2 pressure ulcers (PUs), provides the
most reliable outcome measure of PU
development.
▪ Patients were recruited from hospital and com-
munity settings and are representative of UK
‘standard care’.
▪ There was no blinded outcome assessment due
to funding and/or capacity within the clinical
research teams.
▪ It is acknowledged that the patient population is
not representative of the general NHS population
through exclusion of patients who had cognition
problems, were very sick or were terminally ill.
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previous cross-sectional studies have focused on pain
associated with existing category ≥2 PUs.3–5
As part of the National Institute for Health Research
(NIHR) funded PU Programme of Research
(PURPOSE),6 we ﬁrst sought to determine the extent of
pain experienced by patients with intact skin on pressure
areas.7 8 We conducted two large multicentre prevalence
surveys in the hospital8 and community7 setting. It was
identiﬁed that 12.6% (233/1769) of hospital patients
with no observable PUs reported pressure area related
pain. In addition, substudies involving patients who con-
sented to a detailed pain assessment, 157 hospital and
37 community patients reported pain on 68.0% (66/97)
and 19/20 (95%) skin sites assessed as grade 1 (ie,
intact skin with non-blanching erythema).7 8
The results indicated the extent of pressure area
related pain in hospital inpatients with skin assessed as
‘normal’ or ‘non-blanching but intact’.
In the second stage of the programme, we explored
the role of pressure area related pain of intact skin as a
predictor of PU development in acute hospital and com-
munity populations.
Aims and objectives
The primary aim was to explore the role of pressure
area related pain as an early predictor of category ≥2
PU development in patients at high risk of PU develop-
ment. Objectives were to:
1. Assess whether the presence/absence of pressure
area related pain is a predictor of category ≥2 PU
development.
2. Identify variables which are independently predictive
of category ≥2 PU development.
METHODS
Study design
We conducted a prospective cohort study involving
acutely ill hospital and community patients at high risk
of PU development. Follow-up was twice weekly for a
maximum of 30 days from registration or until they were
no longer at high risk of PU development or transferred
to a non-participating centre or death.
Setting
Patients were recruited from 26 hospital and community
centres across 18 NHS Trusts in England between 26
October 2009 and 17 November 2011. All centres had PU
prevention and management policies and guidelines based
on national and international guidelines9 including risk
assessment and mattress provision and patients received
care as determined by the attending clinical teams.
Patients
All patients were aged ≥18 years, provided written
informed consent, were able to report the presence/
absence of pressure area related pain, were at high risk
of PU development and indicated as acutely ill.
High risk of PU development was deﬁned as one or
more of the following: (1) bedfast/chairfast and com-
pletely immobile/have very limited mobility according
to the Braden Scale,10 (2) localised skin pain on any
pressure area skin site and (3) category 1 PU on any
pressure area skin site.2 4 11
Indicators of acute illness were deﬁned pragmatically
as one of the following: acute hospital admission to vas-
cular, orthopaedic, medical or care of the elderly spe-
cialties;2 11 new community nursing referral following
hospital discharge to home/intermediate/community
care/hospice/specialist palliative care; existing commu-
nity nursing patient with deterioration in overall condi-
tion or onset of acute illness; new referral to community
nursing due to acute illness, deterioration in existing
condition or care package breakdown.
Patients were not eligible to participate if they were
admitted to obstetrics, paediatrics, day case surgery or
psychiatric wards. Patients were also not eligible if they
were deemed by the attending healthcare professional
to be too unwell to be approached and/or complete the
study assessment schedule, or they had ≥2 existing cat-
egory ≥2 PUs on the following pressure area skin sites:
sacrum, buttocks, heels and hips.
Eligible patients were recruited by the research team
and after written informed consent/witnessed verbal
consent they were registered to the study using a central
24-hour telephone registration system.
Outcomes
The primary outcome was the development of a new cat-
egory ≥2 PU. This was deﬁned on a skin site level basis
before being combined into a patient level outcome
(ﬁgure 1). Secondary outcomes were time to develop-
ment of the ﬁrst PU and development of a category ≥2
PU at the skin site level.
Data sources/measurement
Baseline assessment was conducted by trained clinical
research nurses and included: demographics (age,
gender, setting); a priori risk factors (diabetic status,
history of prior weight loss, body mass index (BMI), mat-
tress category, analgesic use, and Braden subdomains)2 10
and skin and pain status.
Skin assessment was conducted on 13 prespeciﬁed
pressure area skin sites (left and right buttocks, heels,
elbows, ankles, trochanters, ischial tuberosities and
sacrum) and any additional pressure areas identiﬁed by
the research nurse doing the assessment using the
NPUAP/EPUAP PU classiﬁcation.9 PUs were classiﬁed
as category 1–4 or unstageable. In addition, as general
skin condition is predictive of category ≥2 PU develop-
ment,2 12 13 observations of any alteration to intact skin
(eg, redness, scar, excoriation, dry, scaly) were recorded
and the presence of healthy skin or other wounds was
conﬁrmed for each skin site.
Pressure area related pain was deﬁned as pain, sore-
ness or discomfort on any intact pressure area (ie, skin
2 Smith IL, et al. BMJ Open 2017;7:e013623. doi:10.1136/bmjopen-2016-013623
Open Access
status assessed as normal, altered or category 1).7 8 To
determine if patients had localised skin pain on any
pressure area skin site, they were asked two screening
questions with yes or no responses: (1) at any time, do
you get pain, soreness or discomfort at a pressure area
(prompt: back, bottom, heels, elbows or other as appro-
priate to the patient)? and (2) do you think this is
related to either; your PU OR lying in bed for a long
time OR sitting for a long time?7 8
Patients were followed up twice weekly for 30 days post-
registration or until one of the following criteria applied:
(1) no longer at high risk of PU development, (2) trans-
ferred to non-participating centre and (3) death.
Bias
Anonymised screening logs were maintained by centres,
and these were monitored to ensure that centres were
approaching and recruiting appropriate patients. While
blinded end point assessment was not possible, the risk
factor and outcome data were recorded by research staff
independent of the clinical team.
Sample size
For risk factor studies using logistic regression, it is recom-
mended that at least 10 patients with the event of interest
are required for reliable estimation of effects.14 Our
primary model planned to include a maximum of 9 factors
and therefore required at least 90 patients to develop a new
category ≥2 PU. In the absence of prospective data for
community-based patient populations,2 the sample size esti-
mate was based on previous research in hospital
patients,11 13 15 suggesting that ∼15% of patients would
develop a new category ≥2 PU within 30 days of registration.
Therefore, assuming loss to follow-up of 5%, the study
required 632 patients.
A further consideration in appraising the sample size
estimate was the prevalence of pain at study entry. As no
previous work in this ﬁeld had been undertaken, we
considered a range of prevalence rates. We estimated
that if we recruited 600 patients (after accounting for
5% loss to follow-up) with 60 (10%) patients having
pressure-related pain at baseline, this would allow us to
detect a difference of 13.2% between those with and
Figure 1 Derivation of skin site
level and patient level outcomes.
*Evaluable skin sites are such
that skin site level outcome can
be determined as ‘Develops PU’
or ‘Does not develop PU’. Note
that patients had up to nine
assessments in total (baseline
and twice weekly for up to 30
days). PU, pressure ulcer.
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those without pain using a χ2 test (80% power, two-sided
5% signiﬁcance level) assuming 10% of patients without
pain and 23.2% of those with pain developed a new PU
within 30 days, corresponding to an OR of 2.72 with
95% CI of (1.40 to 5.27). As this was an exploratory
study and there was uncertainty around the sample size
assumptions, the proportion of patients with pain at
baseline and PU incidence was monitored by the statis-
tical team and chief investigator and reported to a sub-
group of the Programme Steering Committee.
Statistical methods
All statistical analyses were carried out in SAS V.9.2 and
based on the evaluable patient population. That is, all
patients for whom at least one skin site was evaluable
(ﬁgure 1).
Primary analysis: logistic regression model
Univariable logistic regression was conducted to assess a
priori variables for inclusion in the multivariable logistic
regression model. The a priori variables included the
presence of pressure area related pain on a healthy,
altered skin or category 1 skin site and other risk factors
based on a conceptual framework:16 age, diabetes,
history of prior weight loss, Braden mobility subscale
(completely immobile/very limited mobility vs slightly
limited mobility/no limitation with mobility), presence
of skin alterations, presence of a category 1 PU and
setting (hospital vs community). Candidate variables
were considered to be statistically signiﬁcant and there-
fore associated with the development of a category ≥2
PU if the p value was <0.1 for the associated likelihood
ratio test (LRT). Full stepwise variable selection was con-
ducted to build a multivariable logistic regression model
for the odds of developing a category ≥2 PU. Candidate
variables were retained in the model if their exclusion
led to an increase in deviance with a corresponding
p value that was >0.1 for the associated LRT. ORs, corre-
sponding 95% CIs and p values are presented for the
univariable and ﬁnal multivariable models. The level of
0.1 was chosen in line with recommendations for model
selection in the analysis of binary data.17
Three secondary analyses were conducted as follows.
Overdispersion model: Overdispersion model was under-
taken to determine if the model could be improved by
inclusion of other variables. Further baseline variables
(gender, BMI, Braden Scale domains (activity, friction
and shear, moisture, nutrition and sensory perception),
presence of a category ≥2 PU, presence of chronic
wound and type of mattress)2 16 were considered for
inclusion in the ﬁnal model from the primary analysis
using full stepwise variable selection and the same cri-
teria as for the primary analysis. ORs, corresponding
95% CIs and p values are presented for the additional
univariable and ﬁnal multivariable models.
Accelerated failure time model: Full stepwise variable selec-
tion was considered for each of the following distributions:
Gamma, log-logistic, log-normal and exponential. The
model ﬁt of the ﬁnal models obtained for each distribution
were explored using Cox-Snell residual plots. The Gamma
distribution was observed to be the most appropriate and
so, an accelerated failure time (AFT) model assuming the
Gamma distribution was ﬁtted to the data to explore the
relationship between the presence of pressure area related
pain and time to onset of the ﬁrst new category ≥2 PU.
Univariable analyses were conducted to determine which
variables were associated with time to onset of a new cat-
egory ≥2 PU, and the ﬁnal AFT model was obtained using
full stepwise variable selection with the same criteria as for
the primary analysis. Acceleration factors, corresponding
95% CIs and p values are presented for the additional uni-
variable and ﬁnal multivariable models.
Skin site level model: Nesting of skin sites within patients
was taken into account using a two-level
random-intercept logistic regression model. Univariable
analyses and full stepwise variable selection were con-
ducted using the same selection criteria as for the
primary analysis to obtain the ﬁnal multivariable model.
For this multilevel model, only evaluable skin sites
(ﬁgure 1) were analysed, and the variables considered
for inclusion in the model were modiﬁed to reﬂect the
structure of the data such that age, diabetic status,
history of prior weight loss, Braden mobility, setting and
analgesic use continued to be patient level risk factors.
The presence of pressure area related pain at baseline
was assessed for each skin site and was therefore
included as a skin site level risk factor, and the presence
of skin alterations and the presence of a category 1 PU
were combined into a single skin site level risk factor
(healthy/skin alterations/category 1 PU). ORs, corre-
sponding 95% CIs and p values are presented for the
univariable and ﬁnal multivariable models.
Quantitative variables
Age was considered twice for inclusion in the model as a
categorical variable (<65 years/65–74 years/75–84 years/
≥85 years) and as a continuous variable. The Braden
mobility subscale was dichotomised (completely immo-
bile/very limited mobility vs slightly limited mobility/no
limitation with mobility), and all remaining variables for
inclusion in the primary model were considered to be
binary variables. For the secondary analysis model, BMI
was considered for inclusion as a continuous variable,
the remaining Braden subscales were considered on an
ordinal scale, mattress type was categorised as dynamic
high-risk pressure-relieving/static high-risk pressure-
relieving/non-pressure relieving and the remaining vari-
ables for inclusion in the secondary analysis model for
the primary outcome were considered to be binary
variables.
RESULTS
Patients
A total of 3819 patients were screened for participation
in the study. A total of 1266 were eligible and of these
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634 were registered between 26 October 2009 and 17
November 2011. Reasons for ineligibility and refusals/
non-registration are detailed in ﬁgure 2. Thirty-two
(5.0%) patients did not have any follow-up assessments,
and the analysis population therefore comprised 602
evaluable patients (ﬁgure 2), including 397 (65.9%)
hospital and 205 (34.1%) community evaluable patients.
Baseline characteristics are detailed in table 1. The
median (range) length of follow-up was 27 (1–34) days.
Descriptive data
A total of 152 (25.2%) patients developed 223 new cat-
egory ≥2 PUs during follow-up. There were 464 (77.1%)
patients with pressure area related pain on at least one
Figure 2 Patient flow.
Smith IL, et al. BMJ Open 2017;7:e013623. doi:10.1136/bmjopen-2016-013623 5
Open Access
healthy, altered or category 1 skin site at baseline; 28.0%
(N=130) of these developed a new category ≥2 PU com-
pared to 15.9% (N=22) of those without pain at baseline
(table 2). The summary of worst skin status indicates
that a total of 532 (88.4%) patients had some skin
damage at baseline.
The analysis population of 602 patients had a com-
bined total of 7863 potential skin sites assessed corre-
sponding to 13 prespeciﬁed skin sites for each of the
602 patients and 37 additional ‘other’ skin sites. The
majority (77.5%) of skin sites were observed as being
healthy skin sites, and pain was reported more fre-
quently with severity of skin status (table 3); for
example, 63.1% (351/556) of category 1 skin sites were
observed to have pain compared to 40.3% (342/849) of
skin sites with alterations and 6.4% (390/6096) of
healthy skin sites. After excluding 172 skin sites with an
existing category ≥2 PU, 183 skin sites with no baseline
assessment (eg, amputation or bandage in situ), 7
assessed as another wound and 18 with no follow-up
Table 1 Patient level baseline characteristics by setting
Variable Hospital (N=397) Community (N=205) Total (N=602)
Specialty or place assessed
Vascular 42 (10.6%) 0 (0.0%) 42 (7.0%)
Orthopaedic 155 (39.0%) 0 (0.0%) 155 (25.7%)
Medical 90 (22.7%) 0 (0.0%) 90 (15.0%)
Elderly 32 (8.1%) 0 (0.0%) 32 (5.3%)
Medical/elderly 78 (19.6%) 0 (0.0%) 78 (13.0%)
Patient’s own home 0 (0.0%) 49 (23.9%) 49 (8.1%)
Nursing home 0 (0.0%) 27 (13.2%) 27 (4.5%)
Residential home 0 (0.0%) 18 (8.8%) 18 (3.0%)
Rehabilitation unit 0 (0.0%) 104 (50.7%) 104 (17.3%)
Other place assessed 0 (0.0%) 7 (3.4%) 7 (1.2%)
Age
Mean (SD) 75.6 (12.9) 80.7 (11.7) 77.3 (12.7)
Median (range) 79 (21, 101) 83 (30, 100) 80 (21, 101)
Male 156 (39.3%) 77 (37.6%) 233 (38.7%)
Caucasian 396 (99.7%) 205 (100.0%) 601 (99.8%)
Diabetic 98 (24.7%) 55 (26.8%) 153 (25.4%)
N missing 0 (0.0%) 1 (0.5%) 1 (0.2%)
History of prior weight loss 95 (23.9%) 52 (25.4%) 147 (24.4%)
N missing 0 (0.0%) 1 (0.5%) 1 (0.2%)
BMI
Mean (SD) 27.1 (9.3) 26.0 (9.9) 26.7 (9.5)
Median (range) 25 (11, 94) 24 (11, 111) 25 (11, 111)
N missing 12 (3.0%) 12 (5.9%) 24 (4.0%)
Chronic wound at baseline 75 (18.9%) 52 (25.4%) 127 (21.1%)
N missing 0 (0.0%) 1 (0.5%) 1 (0.2%)
Worst skin status at baseline
Healthy 45 (11.3%) 25 (12.2%) 70 (11.6%)
Alterations to intact skin 99 (24.9%) 55 (26.8%) 154 (25.6%)
Category 1 137 (34.5%) 77 (37.6%) 214 (35.5%)
Category 2 98 (24.7%) 42 (20.5%) 140 (23.3%)
Category 3 10 (2.5%) 3 (1.5%) 13 (2.2%)
Category 4 2 (0.5%) 2 (1.0%) 4 (0.7%)
Unstageable 6 (1.5%) 1 (0.5%) 7 (1.2%)
Analgesic in use 366 (92.2%) 182 (88.8%) 548 (91.0%)
N missing 0 (0.0%) 0 (0.0%) 0 (0.0%)
Braden mobility
Completely immobile 9 (2.3%) 12 (5.9%) 21 (3.5%)
Very limited 204 (51.4%) 58 (58.3%) 262 (43.5%)
Slightly limited 142 (35.8%) 89 (43.4%) 231 (38.4%)
No limitation 42 (10.6%) 46 (22.4%) 88 (14.6%)
Mattress type
Non-pressure relieving 5 (1.3%) 31 (15.1%) 36 (6.0%)
Static pressure-relieving 168 (42.3%) 105 (51.2%) 273 (45.3%)
Dynamic pressure-relieving 224 (56.4%) 68 (33.2%) 292 (48.5%)
Missing 0 (0.0%) 1 (0.5%) 1 (0.2%)
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assessment, 7483 (95.2%) skin sites were evaluable in
terms of obtaining a skin site level outcome and were
therefore considered for the skin site level analysis.
Of the evaluable skin sites, a total of 223 (3.0%) devel-
oped a new category ≥2 PU. The proportion of skin
sites developing a new category ≥2 PU appears to
increase with severity of baseline skin status with 1.1% of
healthy skin sites, 6.4% of altered skin sites and 18.2%
of category 1 PU skin sites observed to develop new cat-
egory ≥2 PUs (table 4). There were 1077 (14.4%) skin
sites with pressure area related pain at baseline and
10.3% of these developed a new category ≥2 PU com-
pared to 1.7% of the skin sites without pressure-related
pain (table 4).
Logistic regression model
In the univariable analysis, diabetic status, presence of
skin alterations, presence of category 1 and pressure
area related pain were statistically signiﬁcantly associated
with the odds of developing a new category ≥2 PU
(table 5). Following full stepwise variable selection, the
ﬁnal model (602 patients) indicates that the odds of
developing a category ≥2 PU were increased for the fol-
lowing variables: category 1 PU (OR 3.25(95% CI (2.17
to 4.86)), p<0.0001), presence of skin alterations (OR
(95% CI)=1.98(1.30 to 3.00), p=0.0014) and presence of
pressure area related pain (OR (95% CI)=1.56 (0.93 to
2.63), p=0.0931) (table 5).
Overdispersion analysis
Univariable analyses of additional variables indicated
that gender, Braden moisture, Braden activity, presence
of a chronic wound and presence of pre-existing cat-
egory 2 PU were statistically signiﬁcantly associated with
the odds of developing a new category ≥2 PU (table 6).
The ﬁnal overdispersion model retained the variables
(category 1 PU, skin alterations and the presence of
pressure-related pain) from the ﬁnal primary analysis
Table 2 Development of PU on a patient level by skin
and pain status
Variable
Develops
new PU
(N=152)
Does not
develop new
PU (N=450) Total (N=602)
Presence of skin alterations at baseline
Yes 109 (29.2%) 264 (70.8%) 373 (62.0%)
No 43 (18.8%) 186 (81.2%) 229 (38.0%)
Presence of category 1 PU at baseline
Yes 105 (36.2%) 185 (63.8%) 290 (48.2%)
No 47 (15.1%) 265 (84.9%) 312 (51.8%)
Presence of pain at a healthy, altered or category 1 PU
skin site
Yes 130 (28.0%) 334 (72.0%) 464 (77.1%)
No 22 (15.9%) 116 (84.1%) 138 (22.9%)
PU, pressure ulcer.
Table 3 Baseline skin and pain assessment on a skin site level basis
Skin classification
Pain yes
N (%)
Pain no
N (%)
Missing
N (%)
Total
N (%)
Healthy skin 390 (6.4%) 5700 (93.5%) 6 (0.1%) 6096 (77.5%)
Skin alterations 342 (40.3%) 504 (59.4%) 3 (0.4%) 849 (10.8%)
Category 1 351 (63.1%) 205 (36.9%) 0 (0.0%) 556 (7.1%)
Category 2 116 (78.4%) 32 (21.6%) 0 (0.0%) 148 (1.9%)
Category 3 13 (100%) 0 (0.0%) 0 (0.0%) 13 (0.2%)
Category 4 3 (75.0%) 1 (25.0%) 0 (0.0%) 4 (0.1%)
Unstageable 6 (85.7%) 1 (14.3%) 0 (0.0%) 7 (0.1%)
Unable to assess 6 (7.6%) 52 (65.8%) 21 (26.6%) 79 (1.0%)
Not applicable 2 (2.3%) 26 (29.9%) 59 (67.8%) 87 (1.1%)
Other wound 0 (0.0%) 6 (85.7%) 1(14.3%) 7 (0.1%)
Classification missing 0 (0.0%) 0 (0.0%) 17 (100%) 17 (0.2%)
Total 1229 (15.6%) 6527 (83.0%) 107 (1.4%) 7863 (100.0%)
NB: 602 patients. Each patient had 13 skin assessments and there were 37 ‘other’ sites assessed. The overall total therefore corresponds to
(602×13)+37=7863 skin assessments.
Table 4 Development of category ≥2 PU by pain and
skin assessments on a skin site level basis
Variable
Develops
new PU
(N=223)
Does not
develop
new PU
(N=7260)
Total
(N=7483*)
Pain
Pain yes 111 (10.3%) 966 (89.7%) 1077 (14.4%)
Pain no 112 (1.7%) 6294 (98.3%) 6406 (85.6%)
Skin status
Healthy
skin
68 (1.1%) 6014 (98.9%) 6082 (81.3%)
Alterations
to intact
skin
54 (6.4%) 792 (93.6%) 846 (11.3%)
Category 1 101 (18.2%) 454 (81.8%) 555 (7.4%)
*Note that 172 skin sites with an existing Category ≥2 PU, 183
skin sites with no baseline assessment (eg, amputation or
bandage in situ) and 25 with no follow-up assessment were
excluded leaving a total of 7483 skin sites for analysis.
PU, pressure ulcer.
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model and the presence of pre-existing category 2 PU
(OR (95% CI)=2.09 (1.35 to 3.23), p=0.0009), presence
of chronic wound (OR (95% CI)=1.66 (1.06 to 2.62),
p=0.0277) and Braden Activity subscale (p value for
overall analysis of effects=0.0476). Within this model, the
estimate of the odds of category ≥2 PU development in
the presence of pressure area related pain increased
(OR (95% CI)=1.85 (1.07 to 3.20), p=0.0271) (table 6).
Accelerated failure time model
The univariable AFT analyses indicated that age, pres-
ence of skin alterations, Braden mobility, presence of
category 1 PU and presence of pressure area related
pain were statistically signiﬁcantly associated with
increased rate of category ≥2 PU development (table 7).
The ﬁnal AFT model included presence of a category 1
PU (AF (95% CI)=2.32 (1.73 to 3.12), p<0.0001) and pres-
ence of pressure area related pain (AF (95% CI)=2.28 (1.59
to 3.27), p<0.0001). The model indicates that patients are
likely to develop a category ≥2 PU 2.32 times faster com-
pared to patients who do not have a category 1 PU (AF
(95% CI)=2.32 (1.73 to 3.12)). In addition, patients with
pressure area related pain are likely to develop a category
≥2 PU 2.28 times faster (95% CI (1.59 to 3.27)) compared
to patients who do not have pressure-related pain.
Skin site level model
The univariable analyses indicated that skin status and
the presence of pain were statistically signiﬁcantly asso-
ciated with the odds of developing a category ≥2 PU at
the same skin site (table 8).
The ﬁnal multivariable multilevel logistic regression
model obtained after full stepwise variable selection
indicates that skin status and the presence of
pressure-related pain are predictive of PU development
at the same skin site, after adjusting for patient variation,
that is the clustering of skin sites within patients: pres-
ence of skin alterations (OR (95% CI)=4.65 ((3.01 to
7.18), p<0.0001, compared to healthy skin), presence of
a category 1 PU (OR (95% CI)=17.30 (11.09 to 27.00),
p<0.0001, compared to healthy skin) and presence of
pressure area related pain (OR (95% CI)=2.25 (1.53 to
3.29), p<0.0001).
DISCUSSION
Statement of principal findings
This is the ﬁrst risk factor study to investigate pain as a
risk factor for PU development and found that pain was
an independent predictor of category ≥2 PU develop-
ment in high risk hospital and community patients with
acute illness. There was signiﬁcant evidence that the
presence of pressure area related pain is an independ-
ent predictor for developing a category ≥2 PU, after
adjusting for skin status at baseline, across all four multi-
variable models. On a patient level, there was marginal
evidence that the presence of pain increased the odds
for developing a category ≥2 PU by 30 days of follow-up
(primary end point), and signiﬁcant evidence that the
presence of pressure area related pain also accelerates
the time to developing a category ≥2 PU, after adjusting
for other important covariates. On a skin site level,
Table 5 Primary analysis (patient level): logistic regression models
Covariate OR 95% CI p Value
Univariable analyses
Age (continuous) 1.01 0.99 to 1.022 0.3936
Age (categorical) (reference=‘less than 65 years’)
85 years or older 1.31 0.73 to 2.35 0.4192
65–74 years 1.20 0.63 to 2.29 0.3885
75–84 years 1.17 0.65 to 2.08 0.2996
Diabetic status* (yes vs no) 1.45 0.97 to 2.18 0.0722
History of weight loss† (yes vs no) 1.04 0.68 to 1.60 0.8462
Braden mobility (1 or 2 vs 3 or 4) 1.21 0.84 to 1.76 0.3055
Skin alterations (yes vs no) 1.79 1.20 to 2.66 0.0045
Category 1 PU (yes vs no) 3.20 2.63 to 4.74 <0.0001
Setting (hospital vs community) 0.92 0.62 to 1.35 0.6576
Analgesic use (yes vs no) 0.87 0.46 to 1.62 0.6542
Pressure-related pain on healthy, altered
or category 1 skin site (yes vs no)
2.05 1.25 to 3.38 0.0047
Final multivariable model from primary analysis
Category 1 PU (yes vs no) 3.25 2.17 to 4.86 <0.0001
Skin alterations (yes vs no) 1.98 1.30 to 3.00 0.0014
Pressure-related pain on healthy, altered or Category 1
skin site (yes vs no)
1.56 0.93 to 2.63 0.0931
Bold values indicate statistical significance.
*Missing diabetic status set to ‘no’ for one patient.
†Missing history of prior weight loss status set to ‘no’ for one patient.
PU, pressure ulcer.
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Table 7 Analysis of time to PU development (patient level): Accelerated Failure Time models
Covariate
Ratio* of time to developing
new Category ≥2 PU 95% CI p Value
Univariable analyses
Age (continuous) 1.01 1.00 to 1.03 0.0354
Skin alterations (yes vs no) 1.40 0.99 to 1.97 0.0593
Analgesic use (yes vs no) 1.05 0.61 to 1.83 0.8577
Braden mobility (1 or 2 vs 3 or 4) 1.37 1.00 to 1.87 0.0498
Category 1 PU (yes vs no) 2.63 1.93 to 3.58 <0.0001
Diabetic (yes vs no) 1.24 0.85 to 1.80 0.2591
History of prior weight loss (yes vs no) 0.90 0.62 to 1.30 0.5715
Pain (yes vs no) 2.68 1.86 to 3.86 <0.0001
Setting (Hospital vs community) 1.13 0.81 to 1.58 0.4652
Final multivariable AFT model
Category 1 PU (yes vs no) 2.32 1.73 to 3.12 <0.0001
Pressure-related pain (yes vs no) 2.28 1.59 to 3.27 <0.0001
Bold values indicate statistical significance.
Number in final model=602.
*Ratio corresponds to the acceleration factor.
PU, pressure ulcer.
Table 6 Overdispersion analysis (patient level): logistic regression models
Covariate OR 95% CI p Value
Univariable analyses
Gender (female vs male) 0.72 0.49 to 1.04 0.0780
BMI (continuous) 1.00 0.99 to 1.02 0.6702
Braden sensory (reference=No impairment)
Slightly Limited 0.92 0.54 to 1.58 0.6886
Very Limited 0.41 0.05 to 3.40
Braden Moisture (reference=Rarely moist)
Occasionally moist 1.83 1.22 to 2.74 0.0277
Very moist 1.11 0.51 to 2.44
Constantly moist 2.39 0.39 to 14.55
Braden activity (reference=Bedfast)
Chairfast 1.83 1.05 to 3.19 0.0775
Walks occasionally 1.43 0.77 to 2.65
Walks frequently 0.75 0.23 to 2.40
Braden nutrition (reference=Excellent)
Adequate 0.93 0.59 to 1.47 0.6058
Probably inadequate 1.26 0.77 to 2.06
Very poor 1.10 0.37 to 3.23
Braden friction and shear (reference=No apparent problem)
Potential problem 1.06 0.62 to 1.82 0.8036
Problem 1.22 0.64 to 2.36
Mattress category (reference=dynamic high risk pressure relieving
Static risk pressure relieving 1.28 0.87 to 1.87 0.2430
Non-pressure relieving 0.95 0.41 to 2.17
Chronic wound (yes vs no) 1.89 1.24 to 2.88 0.0032
Category ≥2 PU (yes vs no) 1.70 1.15 to 2.53 0.0083
Final multivariable model from secondary overdispersion analysis
Category 1 PU (yes vs no) 3.20 2.11 to 4.85 <0.0001
Skin alterations (yes vs no) 1.90 1.24 to 2.91 0.0032
Pressure-related pain on healthy, altered or category 1 skin site (yes vs no) 1.85 1.07 to 3.20 0.0271
Category 2 PU (yes vs no) 2.09 1.35 to 3.23 0.0009
Braden activity: Chairfast vs Bedfast 1.86 1.03 to 3.36 0.0476
Braden activity: Walks occasionally vs Bedfast 1.19 0.62 to 2.29
Braden Activity: Walks frequently v Bedfast 0.71 0.21 to 2.46
Chronic wound (yes vs no) 1.66 1.06 to 2.62 0.0277
Bold values indicate statistical significance.
BMI, body mass index; PU, pressure ulcer.
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presence of pain is a predictor for developing a category
≥2 PU on the same skin site by 30 days of follow-up,
after adjusting for skin status and between patient vari-
ation. Other risk factors that emerged include the pres-
ence of a category 1 PU and alterations to intact skin at
baseline, which is consistent with previous studies which
have included category 1 (or equivalent and other skin
status variables in multivariable modelling).2 11 15 18 19
An unexpected ﬁnding was the high proportion of
patients (77.1%) who reported pain at baseline; while a
number of these patients also had category 1 PUs, the
extent of the problem was underestimated in our
sample size estimate.
Strengths and weaknesses of the study
The study was designed to incorporate key quality cri-
teria for the conduct and reporting of risk factor/prog-
nostic factor studies20–28 to promote generalisability and
minimise bias, including an a priori sample size esti-
mate, risk factors informed by a conceptual framework,
risk factor and outcome assessment by a trained clinical
research team independent of the clinical team. The
majority of patients received the recommended National
Institute for Health & Care Excellence (NICE) standard
mattress provision of either high speciﬁcation foam or
alternating pressure mattresses29 and members of the
research team did not alter standard care provision.
Limitations of the study included a lack of blinded
outcome assessment, which could have been achieved if
baseline and follow-up assessments had been under-
taken by two different research nurses, but there was not
funding or capacity within the clinical research teams
for this approach. It is feasible that they could have
introduced bias to outcome assessment. The feasibility
of using photography for independent blind outcome
assessment is currently being determined as part of the
HTA PRESSURE2 Trial (http://medhealth.leeds.ac.uk/
info/423/skin/1717/pressure_2). It is acknowledged
that the patient population is not representative of the
general NHS population through exclusion of patients
who had cognition problems, were very sick or were ter-
minally ill (ﬁgure 2). However, as pain is a symptom of
underlying inﬂammation and/or nerve damage, we con-
sider that the results are generalisable to the wider
population. In addition, efforts to assess pain, soreness
and discomfort should be made for all patients, includ-
ing those with cognition problems using pain assessment
methods established for this group of patients.30–32 It is
acknowledged that patients with darkly pigmented skin
were under represented in the study.
Strengths and weaknesses in relation to other studies
Building on our previous research11 15 33 34 and in our
attempts to maximise the potential event rate and so
minimise the required sample size, the PU incidence
rate of 25.2% was higher than predicted through inclu-
sion of patients with evidence of acute illness and at
‘high risk’ of PU development. The incidence rate is
comparable to other reports of category ≥2 PU inci-
dence. In our systematic review of risk factor studies,2 19
studies reported incidence rates of grade/stage ≥2
ranging from 10.1% to 45.7% in heterogeneous patient
populations. Of importance in terms of generalisability
was our recruitment of community patients. With the
exception of nursing home populations, we found only
one risk factor cohort study involving community
patients which reported a low incidence rate of 3.2%
(55/1567) of stage 2 PUs, but the study did not target
patients with evidence of acute illness.2 35 The observed
incidence rate in the community patient population was
Table 8 Skin site level analyses: multilevel logistic regression models
Covariate OR 95% CI p Value
Univariable analyses
Age (continuous) 1.01 0.99 to 1.02 0.4808
Diabetic status* (no vs yes) 0.81 0.54 to 1.21 0.3070
History of weight loss† (no vs yes) 1.03 0.68 to 1.57 0.8914
Braden mobility (1 or 2 vs 3 or 4) 1.14 0.80 to 1.64 0.4714
Skin status (reference=healthy skin)
Skin alterations 6.29 4.21 to 9.40 <0.0001
Category 1 PU 27.34 18.5 to 40.4 <0.0001
Setting (hospital vs community) 0.91 0.63 to 1.32 0.6148
Analgesic use (no vs yes) 1.33 1.74 to 2.39 0.3350
Pressure-related pain on healthy, altered or Category 1 skin site (yes vs no) 8.68 6.30 to 11.97 <0.0001
Final multivariable model
Skin status (reference=healthy skin)
Skin alterations 4.65 3.01 to 7.18 <0.0001
Category 1 PU 17.30 11.09 to 27.00 <0.0001
Pressure-related pain on healthy, altered or Category 1 skin site (yes vs no) 2.25 1.53 to 3.29 <0.0001
Bold values indicate statistical significance.
*Missing diabetic status set to ‘no’ for one missing patient.
†Missing history of weight loss status set to ‘no’ for one missing patient.
PU, pressure ulcer.
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26.3%, although it is noteworthy that the majority of
‘community’ patients were recruited from rehabilitation
units, with small numbers recruited in the home. In
terms of risk factors identiﬁed, results are consistent
with ﬁndings of the PU risk factor studies which typically
identify immobility limitations, skin status and/or perfu-
sion in multivariable analysis.2 The patient population is
heterogeneous in terms of healthcare setting, but homo-
genous in terms of the presence of acute illness, with a
high proportion of patients with diabetes (25.4%) and
an aged population (median (range)=80 (21–101)
years) compared to other risk factor studies and indica-
tors of high levels of comorbid disease including
chronic wounds (21.1%) and existing category ≥2 PUs
(27.2%), maximising the generalisability of the study
ﬁndings to those patients where primary and secondary
prevention interventions require targeting (NICE 2005).
It could be argued that the study should have excluded
patients with existing category 1 or category ≥2 PUs, but
the inclusion criteria reﬂect the clinical population
whereby patients with existing pressure injury are at risk
of deterioration or PU development on other skin sites.
The study is the ﬁrst to undertake a skin site level ana-
lysis;2 this type of analysis allows for assessment of risk
factors at patient level, for example diabetes, and at skin
site level such as presence of pain at the same skin site.
In previous PU research, sample size considerations for
multivariable analyses have not been used to inform
study design and only 17 studies identiﬁed in a system-
atic review fulﬁlled the ‘rule of thumb’ sample size esti-
mate of 10 events (or PUs) per variable in the
multivariable model.2 20 23 26 Of those only seven ful-
ﬁlled key quality criteria20–28 including loss to follow-up
of <20%; sufﬁcient presentation of data to assess the
adequacy of the method and analysis and a clear strategy
for model building (variables included and based on a
conceptual framework) and the selected model was
adequate for the design.12 19 34 36–39
Meaning of the study: possible explanations and
implications for clinicians and policymakers
We have established that the presence of pain increases
the risk of category ≥2 PU development and accelerates
time to development. This area of practice requires
improved assessment, incorporation into risk assessment
and treatment strategies to alleviate pain and reduce cat-
egory ≥2 PU development by pressure relief/reduction.
Following these results, the presence of pressure-related
pain has been incorporated into the PURPOSE-T a PU
risk assessment framework developed as part of the
PURPOSE programme (http://medhealth.leeds.ac.uk/
info/423/skin/1739/purpose_risk_assessment_framework_
raf_work_package).
Unanswered questions and future research
In our programme of work,4 6–8 we have established that
pressure area related pain is common in hospital and
community patients with intact skin areas and this study
which is the ﬁrst risk factor study to investigate its role
suggests that pain is a factor independently predictive of
subsequent category ≥2 PU development. This study is
the ﬁrst to undertake a skin site level analysis which
allowed skin site-related factors to be taken into account,
however further work is required to improve the statis-
tical methodology in this area by using more of the
information collected in PU research. Further replica-
tion studies are required, and skin site level analyses
should be considered in addition to patient level ana-
lyses for future PU research.
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